（文章来源：每日经济新闻） 每经AI快讯，8月1日，午后中药板块持续逆势拉升，天目药业、华森制药涨停，生物谷一度触及30%涨 停，新光药业、大唐药业涨超10%，亚宝药业、沃华医药、陇神戎发、粤万年青等跟涨。 ...

Group 1 - The A-share traditional Chinese medicine sector is experiencing a significant upward trend, with companies like Tianmu Pharmaceutical and Huasen Pharmaceutical hitting the daily limit increase [1] - Biotech Valley reached a peak of 30cm limit increase, indicating strong market interest and investor confidence [1] - Other companies such as New Light Pharmaceutical and Datang Pharmaceutical saw increases of over 10%, reflecting a broader positive movement in the sector [1] Group 2 - Additional companies including Yabao Pharmaceutical, Wohua Pharmaceutical, Longshen Rongfa, and Guangdong Wannianqing also showed gains, contributing to the overall bullish sentiment in the traditional Chinese medicine market [1]

证券日报网讯陇神戎发（300534）7月31日在互动平台回答投资者提问时表示，公司坚持以市场为导 向，强化内外部协同创新，深耕主打品种二次开发的同时，积极开展新产品的研发工作。 ...

今日焦点 宁德时代：上半年实现净利润305亿元同比增长33.02% 宁德时代公告，上半年实现收入1789亿元，同比增加7.27%；净利润305亿元，同比增长33.02%。报告 期内，本集团实现毛利448亿元，相比2024年同期增加14.45%；综合毛利率为25.02%，相比2024年同期 的23.45%上升1.57个百分点。 上纬新材：多次触及股票交易异常波动和严重异常波动情形明起停牌核查 上纬新材公告称，公司股票自2025年7月9日至7月30日期间多次触及股票交易异常波动及严重异常波动 情形。公司将于7月31日开市起停牌，预计停牌时间不超过3个交易日。公司基本面未发生重大变化，但 股票交易价格已严重脱离基本面，投资者参与交易可能面临较大市场风险。此外，公司股票价格涨幅显 著高于同期相关指数涨幅，换手率显著高于前期水平，市盈率显著高于行业平均水平。公司主营业务和 生产经营未发生重大变化，收购方未来十二个月内不存在资产重组计划，但控制权变更事项仍存在重大 不确定性风险。 金橙子：筹划购买萨米特光电55%股权，股票停牌 金橙子公告称，公司正在筹划以发行股份及支付现金的方式购买长春萨米特光电科技有限公司55%的股 ...

Company Developments - Company announced that its subsidiary, Gansu Puan Pharmaceutical Co., Ltd., received two Clinical Trial Supplement Approval Notices from the National Medical Products Administration on July 30 [1] - The approval allows for the continuation of clinical trials for the drug Brupiprazole oral film, specifically adding 0.5mg and 1mg specifications for the treatment of schizophrenia [1] - The company reported a revenue of 1.039 billion yuan for 2024, a decrease of 3.79% year-on-year, and a net profit attributable to shareholders of 25.8046 million yuan, down 58.14% year-on-year [2] Industry Insights - The company is optimistic about the prospects in the health sector and is actively developing health products, including Huangqi Danggui capsules and plant-based beverages [3] - Recent government policies have been introduced to support the innovation and development of traditional Chinese medicine, which is expected to enhance the quality and market demand for traditional Chinese medicine products [3] - The aging population is increasing the demand for disease prevention and chronic disease management, which is expected to further expand the market for traditional Chinese medicine products [3]

Core Viewpoint - Longshen Rongfa (300534.SZ) announced that its subsidiary, Gansu Puan Pharmaceutical Co., Ltd., received two approval notices from the National Medical Products Administration for clinical trial supplement applications on July 30, 2025 [1] Group 1 - The clinical trial for the drug Bupropion oral dissolving film has been approved to add specifications of 0.5mg and 1mg [1] - Bupropion oral dissolving film is intended for the treatment of schizophrenia [1] - The supplement application primarily aims to increase the relevant specifications for the clinical trial, which will continue to be conducted [1] Group 2 - According to China's drug registration laws and regulations, after obtaining the clinical trial approval notice, the drug must undergo clinical trials and receive review and approval from the National Medical Products Administration before it can be produced and marketed [1]

Core Viewpoint - The company announced that its subsidiary, Puan Pharmaceutical, received approval from the National Medical Products Administration for two supplementary applications for clinical trials of the drug Brivaracetam in 0.5mg and 1mg specifications, which are intended for the treatment of schizophrenia [1] Group 1 - The approval includes the addition of new specifications for the clinical trials of Brivaracetam, indicating ongoing development in the treatment of schizophrenia [1] - Clinical trials will continue following the approval, and the drug must undergo further evaluation and approval by the National Medical Products Administration before it can be manufactured and marketed [1]

Core Viewpoint - The company, Longshen Rongfa, announced that its subsidiary, Gansu Puan Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for two supplementary applications for clinical trials of the drug Brivaracetam oral film, which is intended for the treatment of schizophrenia [1] Group 1 - The approval includes the addition of two new specifications: 0.5mg and 1mg [1] - The supplementary application was accepted on May 20 and meets the requirements for drug registration [1] - The clinical trials for Brivaracetam oral film can continue as per the approved content [1]

Core Viewpoint - The company announced that its subsidiary, Puan Pharmaceutical, received approval from the National Medical Products Administration for two supplementary applications for clinical trials of the drug Brivaracetam oral film in 0.5mg and 1mg specifications, which are intended for the treatment of schizophrenia [1] Group 1 - The approval includes the addition of new specifications for the clinical trial of Brivaracetam oral film [1] - The clinical trial work will continue following the approval, as per the requirements of China's drug registration laws and regulations [1] - The drug must undergo clinical trials and receive further review and approval from the National Medical Products Administration before it can be produced and marketed [1]

证券代码：300534 证券简称：陇神戎发 公告编号：2025-051 甘肃陇神戎发药业股份有限公司 关于控股子公司获得药物临床试验补充申请批准通知书 的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 甘肃陇神戎发药业股份有限公司（以下简称"公司"）控股子公司甘肃普安 制药股份有限公司（以下简称"普安制药"）于 2025 年 7 月 30 日收到国家药品 监督管理局核准签发的 2 份《药物临床试验补充申请批准通知书》，现将相关情 况公告如下： 一、《药物临床试验补充申请批准通知书》的主要内容 药物名称：布瑞哌唑口溶膜 受理号：CXHB2500137、CXHB2500138 通知书编号：2025LB00513、2025LB00514 根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 5 月 20 日受理的布瑞哌唑口溶膜为已获得批准的药物临床试验申请（受理号：C X H L 2 5 0 0 0 8 2，通知书编号 2025LP00911）的补充申请，此次药物临床试验补充 申请符合药品注册的有关要求，同意本品按照批准内容继续开展临床试验。批准 ...